---
title: "Disc Medicine, Inc. (IRON.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IRON.US.md"
symbol: "IRON.US"
name: "Disc Medicine, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T23:45:49.175Z"
locales:
  - [en](https://longbridge.com/en/quote/IRON.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IRON.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IRON.US.md)
---

# Disc Medicine, Inc. (IRON.US)

## Company Overview

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.discmedicine.com](https://www.discmedicine.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.13 | 454 | - | - | - |
| PB | 3.56 | 282 | 5.15 | 3.54 | 3.09 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 92% |
| Overweight | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 67.03 |
| Highest Target | 128.00 |
| Lowest Target | 79.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IRON.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IRON.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IRON.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IRON.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**